IGMM, CNRS Univ. Montpellier, Montpellier, France.
IRCM, INSERM ICM, Univ. Montpellier, Montpellier, France.
Cancer Res. 2017 May 15;77(10):2722-2734. doi: 10.1158/0008-5472.CAN-16-0707. Epub 2017 Mar 10.
The cell proliferation antigen Ki-67 is widely used in cancer histopathology, but estimations of Ki-67 expression levels are inconsistent and understanding of its regulation is limited. Here we show that cell-cycle regulation underlies variable Ki-67 expression in all situations analyzed, including nontransformed human cells, normal mouse intestinal epithelia and adenomas, human cancer cell lines with or without drug treatments, and human breast and colon cancers. In normal cells, Ki-67 was a late marker of cell-cycle entry; Ki-67 mRNA oscillated with highest levels in G while protein levels increased throughout the cell cycle, peaking in mitosis. Inhibition of CDK4/CDK6 revealed proteasome-mediated Ki-67 degradation in G After cell-cycle exit, low-level Ki-67 expression persisted but was undetectable in fully quiescent differentiated cells or senescent cells. CDK4/CDK6 inhibition and in tumors in mice caused G cell-cycle arrest and eliminated Ki-67 mRNA in RB1-positive cells but had no effect in RB1-negative cells, which continued to proliferate and express Ki-67. Thus, Ki-67 expression varies due to cell-cycle regulation, but it remains a reliable readout for effects of CDK4/CDK6 inhibitors on cell proliferation. .
细胞增殖抗原 Ki-67 在癌症组织病理学中被广泛应用,但 Ki-67 表达水平的评估结果并不一致,其调控机制也知之甚少。本研究表明,细胞周期调控是导致所有分析情况下 Ki-67 表达出现差异的根本原因,包括未转化的人类细胞、正常的小鼠肠上皮和腺瘤、有或无药物处理的人类癌细胞系,以及人类乳腺癌和结肠癌。在正常细胞中,Ki-67 是细胞周期进入的晚期标志物;Ki-67 mRNA 在 G1 期波动最大,而蛋白质水平在整个细胞周期中增加,在有丝分裂期达到峰值。抑制 CDK4/CDK6 会导致蛋白酶体介导的 G1 期 Ki-67 降解。细胞周期退出后,低水平的 Ki-67 表达持续存在,但在完全静止的分化细胞或衰老细胞中无法检测到。在小鼠中,CDK4/CDK6 抑制会导致 G1 期细胞周期阻滞,并消除 RB1 阳性细胞中的 Ki-67 mRNA,但对 RB1 阴性细胞没有影响,这些细胞继续增殖并表达 Ki-67。因此,Ki-67 的表达因细胞周期调控而变化,但它仍然是评估 CDK4/CDK6 抑制剂对细胞增殖影响的可靠指标。